Current and historical daily PE Ratio for ENTO (
Entero Therapeutics Inc
) from 2016 to Jun 19 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Entero Therapeutics stock (ENTO) PE ratio as of Jun 19 2024 is 0.
More Details
Entero Therapeutics Inc (ENTO) PE Ratio (TTM) Chart
Entero Therapeutics Inc (ENTO) PE Ratio (TTM) Historical Data
View and export this data going back to 2016. Start your Free Trial
Total 1253
- 1
- 2
- 3
- 4
- 5
- 6
- 14
Entero Therapeutics PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2024-06-19 | At Loss | 2024-04-16 | At Loss |
2024-06-18 | At Loss | 2024-04-15 | At Loss |
2024-06-17 | At Loss | 2024-04-12 | At Loss |
2024-06-14 | At Loss | 2024-04-11 | At Loss |
2024-06-13 | At Loss | 2024-04-10 | At Loss |
2024-06-12 | At Loss | 2024-04-09 | At Loss |
2024-06-11 | At Loss | 2024-04-08 | At Loss |
2024-06-10 | At Loss | 2024-04-05 | At Loss |
2024-06-07 | At Loss | 2024-04-04 | At Loss |
2024-06-06 | At Loss | 2024-04-03 | At Loss |
2024-06-05 | At Loss | 2024-04-02 | At Loss |
2024-06-04 | At Loss | 2024-04-01 | At Loss |
2024-06-03 | At Loss | 2024-03-28 | At Loss |
2024-05-31 | At Loss | 2024-03-27 | At Loss |
2024-05-30 | At Loss | 2024-03-26 | At Loss |
2024-05-29 | At Loss | 2024-03-25 | At Loss |
2024-05-28 | At Loss | 2024-03-22 | At Loss |
2024-05-24 | At Loss | 2024-03-21 | At Loss |
2024-05-23 | At Loss | 2024-03-20 | At Loss |
2024-05-22 | At Loss | 2024-03-19 | At Loss |
2024-05-21 | At Loss | 2024-03-18 | At Loss |
2024-05-20 | At Loss | 2024-03-15 | At Loss |
2024-05-17 | At Loss | 2024-03-14 | At Loss |
2024-05-16 | At Loss | 2024-03-13 | At Loss |
2024-05-15 | At Loss | 2024-03-12 | At Loss |
2024-05-14 | At Loss | 2024-03-11 | At Loss |
2024-05-13 | At Loss | 2024-03-08 | At Loss |
2024-05-10 | At Loss | 2024-03-07 | At Loss |
2024-05-09 | At Loss | 2024-03-06 | At Loss |
2024-05-08 | At Loss | 2024-03-05 | At Loss |
2024-05-07 | At Loss | 2024-03-04 | At Loss |
2024-05-06 | At Loss | 2024-03-01 | At Loss |
2024-05-03 | At Loss | 2024-02-29 | At Loss |
2024-05-02 | At Loss | 2024-02-28 | At Loss |
2024-05-01 | At Loss | 2024-02-27 | At Loss |
2024-04-30 | At Loss | 2024-02-26 | At Loss |
2024-04-29 | At Loss | 2024-02-23 | At Loss |
2024-04-26 | At Loss | 2024-02-22 | At Loss |
2024-04-25 | At Loss | 2024-02-21 | At Loss |
2024-04-24 | At Loss | 2024-02-20 | At Loss |
2024-04-23 | At Loss | 2024-02-16 | At Loss |
2024-04-22 | At Loss | 2024-02-15 | At Loss |
2024-04-19 | At Loss | 2024-02-14 | At Loss |
2024-04-18 | At Loss | 2024-02-13 | At Loss |
2024-04-17 | At Loss | 2024-02-12 | At Loss |
Entero Therapeutics Inc (ENTO) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
![Entero Therapeutics Inc Entero Therapeutics Inc logo](https://static.gurufocus.com/logos/0C0000B4UJ.png?14)
Entero Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US05502L1052
Description
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.